It is not well understood how the human Mediator complex, transcription factor IIH and RNA polymerase II (Pol II) work together with activators to initiate transcription. Activator binding alters Mediator structure, yet the functional consequences of such structural shifts remain unknown. The p53 C terminus and its activation domain interact with different Mediator subunits, and we find that each interaction differentially affects Mediator structure; strikingly, distinct p53-Mediator structures differentially affect Pol II activity. Only the p53 activation domain induces the formation of a large pocket domain at the Mediator-Pol II interaction site, and this correlates with activation of stalled Pol II to a productively elongating state. Moreover, we define a Mediator requirement for TFIIH-dependent Pol II C-terminal domain phosphorylation and identify substantial differences in Pol II C-terminal domain processing that correspond to distinct p53-Mediator structural states. Our results define a fundamental mechanism by which p53 activates transcription and suggest that Mediator structural shifts trigger activation of stalled Pol II complexes.
a r t i c l e s Although every gene does not rely on the same set of regulatory factors for its expression, a subset of general transcription factors, including Mediator and transcription factor IIH (TFIIH), seem to be required to transcribe the majority of protein-coding genes 1 . Comparatively little is known about the Mediator complex, due in part to its more recent discovery in human cells 2 and a lack of identifiable functional domains within its 26 subunits. Yet it is clear that Mediator is the primary regulator of the pre-elongation complex (PEC), which includes TFIIA, TFIIB, TFIID, TFIIE, TFIIF, TFIIH, Mediator and Pol II (see Supplementary Note for description of this terminology). The PEC, in various forms, is responsible for genome-wide transcriptional regulation of protein-coding genes and Mediator physically or functionally interacts with most components of the 3.5-MDa PEC, including a tight association with Pol II itself [3] [4] [5] [6] . Thus, potential structural changes in the 1.2-MDa Mediator complex might significantly affect gene expression by altering PEC structure and function.
The p53 transcription factor has been identified as a key regulator of aging in mammals 7, 8 and is one of the most widely studied proteins in cancer biology because of its strong tumor-suppressor function 9 . Despite this, the molecular mechanisms by which p53 actually activates transcription are not well defined. It is not clear how the mere presence of p53 at a promoter translates into gene activation, particularly because many p53 target genes show characteristics of genes poised for activation: their promoters contain preloaded Pol II but remain inactive 10 . Thus, one mechanism by which p53 likely activates gene expression is via postrecruitment events that trigger Pol II promoter clearance and transcription elongation. Precisely how p53 might control such postrecruitment events remains unclear, but one plausible means involves Mediator, which appears to regulate postrecruitment events in Elk-1-dependent Egr1 gene activation 11 .
Past work has revealed that p53 binds two different Mediator subunits, Med17 and Med1. The N-terminal activation domain of p53 (p53AD) interacts specifically with Med17, whereas a different domain in p53 binds directly to Med1 (refs. 12, 13) . Notably, mutation of two residues in the p53AD (L22Q and W23S in human p53; hereafter termed p53QS) prevents expression of most p53 target genes and leads to tumor formation [14] [15] [16] . Thus, p53AD is critical for the tumor-suppressor function of p53 (ref. 17) . As expected, the p53QS mutations prevent p53AD from interacting with Med17; however, the second, p53-Med1 interaction is unaffected by the p53QS mutations 13 , indicating that p53QS can still bind Mediator (via the Med1 subunit) yet is defective in activating transcription. This suggests that the p53AD-Mediator interaction has an additional role in gene activation that does not involve Mediator recruitment.
Over the past 40 years, the factors required to initiate gene expression have been identified. A major unanswered question that remains is how these factors work together with transcription factors, such as p53, to activate gene expression. About eight years ago, it was discovered that activator binding could trigger significant structural shifts in the human Mediator complex 18 , suggesting a simple means to regulate its activity. Yet it was unclear whether such structural shifts might serve any regulatory function. Here we describe a structural and functional analysis of p53-Mediator. Our results suggest that p53-induced structural shifts in Mediator are essential for regulating postrecruitment steps in gene activation. In particular, a specific p53AD-Mediator structural shift appears to coordinate activation a r t i c l e s of TFIIH and Pol II in the PEC, whereas alternate Mediator structures maintain stalled Pol II in an inactive state. The ability of p53 to indirectly control the activity of TFIIH and Pol II via structural changes in Mediator offers fundamental insight into how p53 functions as an activator of transcription. Perhaps more noteworthy, the structural shift linked to activation by p53-Mediator is also observed in other activator-Mediator structures, suggesting a unifying theme in transcription activation.
RESULTS

PEC assembly can occur independently of p53
Although past studies have shown that p53AD binds directly to Med17 (ref. 13) , the p53 domain responsible for interaction with Med1 was not known 12 . To better define this second, Med1interacting domain in p53, we performed a series of experiments (see Supplementary Results and Supplementary Figs. 1 and 2) that mapped this domain to 31 residues within its C terminus (residues 363-393; p53CTD). At 1.2 MDa, Mediator represents a major subassembly within the PEC. As an independent domain that interacts with Mediator, we examined whether the p53CTD alone might promote PEC assembly on a promoter template. We completed a series of immobilized template assays in which we examined promoter occupancy as a function of p53AD or p53CTD. We performed these experiments essentially as described 19 . Briefly, we incubated immobilized GAL4 DNA templates with either GAL4-p53CTD or with a GAL4-p53AD/ CTD fusion protein, followed by addition of HeLa nuclear extract, which contains the full complement of PEC factors. After a series of washes, we detected promoter-bound factors by immunoblotting. The occupancy of PEC components TFIIB, TFIID, TFIIE, TFIIF, TFIIH, Pol II and Mediator was similar in both experiments (Fig. 1a) . In addition, using purified factors from a reconstituted transcription system 20 , we examined PEC assembly at the GAL4 promoter in the context of chromatin. We assessed factor binding with a chromatin sedimentation assay as described 20 . As expected, the p53CTD alone enabled assembly of the PEC on chromatin templates ( Supplementary Fig. 3 ). Chromatin sedimentation assays completed at the native HDM2 promoter with wild-type (WT) and p53QS mutant p53 tetramers revealed similar results, that is, p53QS tetramers, which possess a mutation in p53AD that prevents the Figure 1 The p53AD is not required for PEC assembly in vitro or in cells. (a) Immobilized template assays. Occupancy of PEC components in the presence of promoter-bound GAL4-p53CTD or a GAL4-p53AD/CTD fusion protein. Note that endogenous p53 will not bind the GAL4 promoter. Antibodies: Pol II, Rpb1; Mediator, Med1; IIH, ERCC3; IIF, Rap74; IIE, IIEα; IID, TBP. (b) Schematic of WT p53 and mutant p53 proteins used in this study. (c) ChIP assays at HDM2 in p53-null HCT116 cells following transfection with WT p53 (WT, blue bars), p53 with a truncated CTD (residues 1-362; ΔCTD, red bars) or p53QS mutant (QS, yellow bars). Data from no transfection controls (No T, green bars) are also shown. The probe location in red represents the promoter/transcription start site. Note that PEC factors appear to be preloaded at the promoter, as observed previously 21 . *ChIP output was normalized to WT p53, typically from C primer. For clarity, error bars are not shown but can be viewed in Supplementary Figure 14 . a r t i c l e s p53AD-Med17 interaction but not the p53CTD-Med1 interaction, were also capable of PEC assembly, as was WT p53, on the native HDM2 promoter (data not shown). Thus, the chromatin sedimentation and immobilized template experiments suggest that PEC recruitment does not require p53AD. Notably, these results are supported by chromatin immunoprecipitation (ChIP) data in HCT116 cells (described below). To further assess whether PEC occupancy might be dependent on p53AD, we expressed WT p53, the p53QS mutant or a p53CTD deletion mutant (p53ΔCTD) in p53-null HCT116 cells ( Supplementary  Fig. 4a ). We then performed ChIP assays at the HDM2 gene to determine if differential promoter occupancy would be observed. Each p53 protein tested (WT p53, p53ΔCTD and p53QS, Fig. 1b ) occupied the HDM2 promoter after transfection ( Fig. 1c ). Mediator and Pol II promoter occupancy was largely similar for each p53 protein examined ( Fig. 1c) . In fact, each complex seemed to be preloaded at the HDM2 gene, consistent with past reports 21 . Similarly, the general transcription factors TFIIH, TFIID and TFIIB occupied the HDM2 promoter in the absence of p53 and also in the presence of WT or mutant p53 tetramers ( Fig. 1c) . ChIP assays at the p21 gene yielded similar results ( Supplementary Fig. 4b-d ). Thus, it appears that in cells, as observed in vitro, PEC recruitment does not require WT p53.
p53AD-Mediator and postrecruitment activation of transcription
Past in vitro and in vivo studies have shown that p53AD is critical for activating most p53 target genes [14] [15] [16] . Yet functional assays in yeast have suggested that Mediator recruitment alone can trigger gene activation in vitro and in vivo 22, 23 .
To identify whether p53CTD might functionally resemble p53AD as an activator of transcription, we compared the transcriptional activity of p53AD and p53CTD-two p53 domains capable of recruiting Mediator-in cell-based reporter assays. As expected, p53AD activated transcription, whereas p53CTD was incapable of activating transcription ( Fig. 2a) . To probe this further, we used a chromatinbased reconstituted human transcription system ( Fig. 2b) consisting of highly purified PEC components, including TFIIA, TFIIB, TFIID, TFIIE, TFIIF, TFIIH, Pol II and Mediator 20 (see also Supplementary  Fig. 5a-c) . Note that Mediator was required for transcription in these assays (Fig. 2c, compare lanes 2 and 4) . Strikingly, the p53CTD was incapable of activating transcription in these experiments. In fact, transcript levels with p53CTD matched those without an activator, whereas p53AD showed potent activity in this assay (Fig. 2c , compare lanes 3-5). The inability of p53CTD to activate transcription was not due to a defect in recruiting Mediator or Pol II to the chromatin template, as revealed by chromatin sedimentation assays (described above). Furthermore, primer-extension products of just 85 base pairs are detected from the GAL4 template, indicating that Pol II does not clear the promoter without p53AD. A GAL4-p53AD/CTD fusion protein was also capable of activating transcription, indicating that the p53CTD does not negatively impact the activation function of p53AD in these assays (Fig. 2c, lane 6) . The significance of the p53AD-Mediator interaction was further highlighted by experiments in which recombinant Med17, which competitively blocks p53AD-Mediator binding, was able to repress p53AD-dependent transcription (Fig. 2d , compare lanes 1, 2 and 4). However, recombinant Med17 had no effect on transcription activated by VP16 (Fig. 2d , compare lanes 5, 6 and 8), which interacts with Mediator through the Med25 subunit 24, 25 . Thus, Med17 itself is not a general repressor in this assay but can block activation dependent on p53AD. Incidentally, recombinant Med1, which competes for the p53CTD-Med1 interaction, had little effect on transcript levels (Fig. 2d, compare lanes 1 and 3) , suggesting that the p53CTD-Med1 interaction is not critical for transcription activation in this context. By contrast, recombinant Med1 was a potent repressor of vitamin D receptor-dependent transcription (data not shown), as vitamin D receptor binds Mediator via the Med1 subunit 26 .
Reconstituted transcription assays with the GAL4-p53 proteins were designed to show what p53AD and p53CTD each contributed to Mediator and PEC function. We next examined each p53 domain in its native context: full-length p53, which binds DNA as a tetramer. We expressed full-length p53 in insect cells and isolated it as an intact tetramer, based on gel-filtration chromatography and electron microscopy analysis (Supplementary Fig. 5d-f ). To further define p53AD and p53CTD functions within the tetramer, we also expressed and purified p53ΔCTD and p53QS. We evaluated the transcriptional a r t i c l e s activity of each p53 tetramer in the reconstituted transcription system on the native HDM2 promoter, which is induced by p53 in vivo and contains tandem, consensus p53 binding sites. As expected, p53 tetramers containing intact activation domains (WT p53 and p53ΔCTD) strongly activated transcription from the HDM2 promoter ( Fig. 3a , lanes 4 and 6), whereas the p53QS mutant was unable to activate transcription (Fig. 3a, lane 5) . In fact, the p53QS mutant was functionally equivalent to 'no activator' control experiments (Fig. 3a, lane 3) . Furthermore, chromatin sedimentation assays revealed that WT p53 did not differentially recruit Mediator, Pol II or other PEC components to the HDM2 promoter relative to p53QS (data not shown). Thus, similar to experiments with the GAL4 template, it seemed that PEC occupancy at the HDM2 promoter did not correlate with activation and that, without an intact p53AD, Pol II occupied the promoter but was unable to transition to a productively elongating state (in fact, primer-extension products of just 155 base pairs would be detected from the HDM2 template). As with the GAL4 template experiments, p53-dependent activation at the HDM2 promoter could be blocked with addition of recombinant Med17 (but not Med1, Fig. 3b ), again suggesting that the p53AD-Mediator interaction has a key role in the activation mechanism that does not involve factor recruitment. We next compared the activity of WT p53 with the p53QS or p53ΔCTD mutants in cells. We expressed each protein in p53-null HCT116 cells (Supplementary Fig. 4a ). We compared the ability of each p53 protein to activate transcription at the HDM2 and p21 genes, both of which have been shown to possess stalled Pol II at their respective promoters 21, [27] [28] [29] . HDM2 mRNA levels were consistent with our in vitro transcription results from the native HDM2 promoter: p53QS was unable to activate transcription, whereas WT p53 and p53ΔCTD enhanced HDM2 mRNA levels (Fig. 3c) . Real-time quantitative PCR (RT-qPCR) assays at the p21 gene yielded similar results (Fig. 3d) . Coupled with the data shown in Figures 1 and 2, the data summarized in Figure 3 corroborate numerous in vitro and in vivo studies that link p53AD to activation of p53 target-gene expression [13] [14] [15] [16] , yet these data also show that p53AD is not required for PEC assembly and functions primarily at a postrecruitment step to activate HDM2 or p21 transcription.
Pol II CTD processing and Pol II promoter escape
Within the PEC, the Pol II CTD is phosphorylated by TFIIH, and this correlates with Pol II promoter clearance and transcript elongation. To probe the activity of TFIIH in the PEC, we completed a series of immobilized template kinase assays at the native HDM2 promoter. In these assays, we assembled PECs from purified components-not extracts-so that no contaminating kinase activities would be present. Thus, we assembled purified TFIIA, TFIIB, TFIID, TFIIE, TFIIF, TFIIH, Mediator and Pol II (see ref. 20) on immobilized HDM2 promoter templates together with WT p53, the p53QS mutant or no activator controls. We observed that, despite similar PEC-Pol II occupancy, levels of phosphorylated Pol II CTD were substantially lower in the presence of WT p53 compared with the p53QS mutant or no-activator controls (Fig. 4a) . These results provide evidence that WT p53 triggers transcription activation via rapid Pol II promoter clearance (and thus less Pol II CTD phosphorylation in the PEC), whereas with the p53QS mutant, Pol II remained inactive in the PEC. Indeed, the increased levels of Pol II CTD phosphorylation observed (Fig. 4a, lanes 4 and 6) correspond to inactive PECs, as assessed by reconstituted transcription assays (Fig. 3a, lanes 3 and 5) . Thus, the increased levels of Pol II CTD phosphorylation observed with the p53QS mutant or no-activator control experiments (Fig. 4a, lanes 4  and 6) suggest that Pol II does not efficiently transition to a productively elongating state in the absence of p53AD. The data in Figure 4a also indicate that Pol II CTD phosphorylation did not occur in PECs assembled without Pol II itself (Fig. 4a, lane 2) or without the kinase, Figure 3 p53AD activates stalled Pol II in the context of the native tetramer in vitro and in cells. (a) Reconstituted transcription from the native HDM2 promoter. As with the GAL4 template, transcription was dependent on Mediator and an intact p53AD. Activators tested were WT p53 (WT), p53 with a mutated activation domain (QS) and p53 lacking the CTD (ΔCTD). Each p53 protein was purified as a tetramer. Plot shows mean and s.e.m. from multiple experiments (n = 5, 10, 4 and 4 for lanes 3-6, respectively). (b) As with the GAL4 template ( Fig. 2d) , recombinant Med17 could strongly repress p53-dependent transcription at the HDM2 promoter, whereas recombinant Med1 had little effect. The bar graph shows quantitation of transcripts, with bars representing s.e.m. (n = 10 and 2 for lanes 1 and 2, respectively). Experiments shown in a and b followed the same timeline as shown in Figure 2b and contained the same concentration of HDM2 chromatin template, TFIIA, IIB, IID, IIE, IIF, IIH, Pol II and NTPs.
Mediator and activators were added as shown.
(c,d) Summary of results from RT-qPCR experiments measuring HDM2 (c) or p21 mRNA levels (d) in response to the p53 proteins shown. Experiments were completed in p53-null HCT116 cells; dashed line represents mRNA levels measured in nontransfected control cells. Note that similar mRNA levels observed with WT p53 and p53ΔCTD result from their overexpression upon transfection. When expressed at physiological levels, p53ΔCTD is still observed to activate HDM2 and p21, but to a lesser extent relative to WT p53 due to the decreased ability of p53ΔCTD to stably bind DNA 47 .
a r t i c l e s TFIIH (Fig. 4a, lane 1) , as expected. Somewhat unexpected was the complete dependence on Mediator for TFIIH-dependent phosphorylation of the Pol II CTD (Fig. 4a, compare lanes 3 and 5) , suggesting that, within the PEC, Mediator and TFIIH function synergistically to control Pol II CTD phosphorylation. We also observed this Mediator requirement for Pol II CTD phosphorylation in PECs assembled on GAL4 promoter templates (data not shown).
Having identified a functional interdependence between human Mediator and TFIIH, we next examined whether the p53QS mutation might affect Pol II processing at the HDM2 gene in cells. The human Pol II CTD consists of 52 heptapeptide repeats with the consensus sequence YSPTSPS. The major Pol II S5 CTD kinase is TFIIH, whereas the major Pol II S2 CTD kinase is positive transcription elongation factor b (P-TEFb). We probed the HDM2 gene for S5P and S2P modified forms of the Pol II CTD using ChIP. These experiments revealed that cells expressing the p53QS mutant showed reduced Pol II occupancy in the HDM2 and p21 genes, despite high Pol II occupancy at the promoter. Indeed, we observed reductions in phosphorylated forms of Pol II in the body of the HDM2 and p21 genes (Fig. 4b,c and Supplementary Fig. 6) , providing further evidence that Pol II was not transitioning to a productively elongating state in the absence of an intact p53AD. Note that these ChIP results are entirely consistent with the reconstituted transcription data ( Figs. 2c and 3a) , which clearly showed that p53AD was required for Pol II to transition off the promoter to generate a transcript. Differences in Pol II CTD phosphorylation did not seem to result from differences in the occupancy of distinct Pol II CTD kinases (TFIIH, P-TEFb or CDK8) at the HDM2 or p21 genes, as evaluated by ChIP ( Figs. 1c and 4d,e and Supplementary Figs. 4 and 6) .
The multisubunit negative elongation factor (NELF) complex has been shown to regulate postrecruitment events in transcription initiation 30 . Therefore, we also examined the promoter occupancy of NELF at the HDM2 and p21 genes. These results (described further in Supplementary Results and Supplementary Fig. 7) reveal that, although NELF may play auxiliary roles in regulating HDM2 and p21 expression, NELF does not appear to be required for controlling p53AD-dependent changes in gene expression.
p53AD triggers a structural shift in Mediator distinct from p53CTD
So what is p53AD doing that enables activation of preloaded or stalled Pol II complexes? Although p53 does not contact Pol II directly, p53AD interacts with high affinity to Mediator via the Med17 subunit 13 . Mediator, in turn, interfaces extensively with the Pol II enzyme 4, 6 . Past studies with human Mediator established that its structural state can be altered substantially by transcription-factor binding 18 . In fact, different transcription factors (which can bind different Mediator subunits) are capable of inducing different structural states, establishing a link between the subunit target and the structural state of Mediator. To investigate whether a structural shift might provide a basis for the difference in Mediator activity when bound to p53AD versus p53CTD, we completed electron microscopy analysis and single-particle reconstruction of Mediator bound to either p53AD or p53CTD. The three-dimensional (3D) structures of p53AD-Mediator and p53CTD-Mediator are shown in Figure 5a ,b (see also Supplementary Results, Supplementary Figs. 8-12 and Supplementary Movies 1 and 2) . In each case, Mediator adopts a dramatically different 3D architecture, indicating that, as expected, different Mediator targets (Med17 for p53AD, Med1 for p53CTD) trigger distinct structural changes in the complex. Strikingly, the p53AD-Mediator structure contains a large 'pocket' domain (arrow, Fig. 5a ) that is of sufficient size and shape to accommodate the Pol II enzyme 31 . In fact, Pol II binds Mediator at this site ( Supplementary  Fig. 12c) ; Pol II has also been observed to bind at the pocket site in yeast Mediator 4 . The pocket domain was preserved in the structure of Mediator bound to WT p53 tetramers ( Fig. 5c and Supplementary  Movie 3 ) and the p53ΔCTD tetramer ( Supplementary Fig. 13a and Figure 1c . The probe location in red represents the promoter/transcription start site. *ChIP output was normalized to WT p53, typically from primer C. For clarity, error bars are not shown but can be viewed in Supplementary Figure 15 .
a r t i c l e s Supplementary Movie 4) , each of which shows strong activity in vitro and in cells ( Fig. 3) . By contrast, the p53CTD-Mediator structure lacks this Pol II pocket and does not resemble other activator-bound Mediator structures (Supplementary Fig. 12a) . Instead, p53CTD-Mediator contains a wall of protein density that occupies the Pol II site (Fig. 5b) and appears to represent an inactive structural state. Collectively, these structural data establish a link between p53ADdirected structural changes and Mediator-dependent, postrecruitment activation of Pol II in the PEC.
DISCUSSION
Because of the large size and low abundance of human Mediator, electron microscopy is the only structural technique suited to study this 1.2-MDa complex. Despite the limited resolution of this technique, electron microscopy reconstructions of p53-Mediator clearly define major structural shifts that provide insight into how p53AD coordinately regulates the activity of Mediator, TFIIH and Pol II within the PEC. Notably, Mediator, TFIIH and Pol II are each generally required for expression of protein-coding genes 1 , and the structural and functional data outlined here provide the first demonstration to our knowledge that activator-induced structural shifts in Mediator serve important regulatory functions, including activation of stalled Pol II (Fig. 6) . Past studies of p53 activation at p21 implied a postrecruitment role for Mediator 29 ; our data confirm this and provide evidence for a conformational switching mechanism whereby p53-Mediator activates stalled Pol II complexes at p21 and HDM2. However, not all p53-regulated genes appear to possess promoter-associated Pol II before activation 21 . Thus, alternate regulatory mechanisms may predominate at other genes in the p53 network. It will be interesting to compare how Mediator-PEC assembly and structure might vary during activation of these distinct p53 target genes. It will be also be important to define how Mediator might work together with auxiliary factors, such as NELF and P-TEFb 30 , that likely help enforce the activation of stalled Pol II in different promoter contexts.
Our results also point to a general mechanism that may govern activator-dependent transcription. Each of the activator-bound Mediator structures examined to date has been shown to trigger substantial structural shifts relative to the unbound, activator-free state 18, 31 . In each case-with the exception of the transcriptionally inactive p53CTD-Mediator structure shown here-a defined Pol II pocket domain is a shared feature, suggesting that this structural shift represents a fundamental means by which transcription factors help activate gene expression ( Fig. 7) . Because Mediator physically or functionally interacts with many PEC components, activator-dependent structural shifts may affect multiple or different steps in transcription initiation in different promoter contexts. The structural plasticity of other general transcription factors (including TFIIB and TFIID) suggests that activator-dependent A defined pocket domain is evident in p53AD-Mediator (transcriptionally active), whereas in p53CTD-Mediator (transcriptionally inactive), this region is occupied by a wall of protein density. Bar, 100 Å. Note that the pocket domain corresponds to the Mediator-Pol II interaction site, as shown in Supplementary Figure 12c . (c) The structure of Mediator bound to the WT p53 tetramer (34-Å resolution). Like p53AD-Mediator, the pocket domain represents a prominent structural feature. The volume shown is rendered to 1.4 MDa, the approximate molecular weight of the WT p53-Mediator assembly. The general location of the p53 tetramer is highlighted, with asterisks representing the p53 DNA-binding domains. Larger asterisks are closer to the viewer. Lower panels show views of the docked WT p53 tetramer structure 48 Figure 6 Model outlining how p53AD appears to trigger Pol II promoter escape and transcription elongation. Top, despite full PEC assembly, promoter-proximally stalled Pol II remains unable to transition to a productively elongating state in the absence of the p53AD-directed structural shift in Mediator. Bottom, Mediator structural shifts, orchestrated by p53AD, activate stalled Pol II to transition to a productively-elongating state. This Mediator-dependent activation seems to be triggered by formation of the pocket domain in Mediator, which interfaces extensively with Pol II. Note that the location and path of the Pol II CTD within the PEC has not been clearly defined. a r t i c l e s structural changes in the PEC are a common regulatory strategy [32] [33] [34] [35] . Such a strategy could allow for more diverse transcriptional responses to combinatorial regulatory inputs and provides a straightforward mechanism for regulating transcription after Pol II recruitment.
Structural analysis of p53-Mediator has revealed major differences in its conformational state upon binding either p53AD or p53CTD, and these structural shifts were preserved in the context of the p53 tetramer. In particular, formation of a large pocket domain in Mediator was induced upon binding the WT p53 tetramer or p53AD alone, whereas the pocket domain was clearly absent in the p53CTD-Mediator structure. Using immobilized template and chromatin sedimentation assays, we observed similar promoter occupancy of PEC factors irrespective of p53AD. Yet reconstituted transcription assays revealed an absolute dependence on p53AD for activation of transcription. ChIP and RT-qPCR assays in cells suggest a similar phenomenon: PEC factors (including Mediator, Pol II and TFIIH) were preloaded at the p53-regulated HDM2 and p21 genes, yet an intact p53AD was required for activation of transcription. We also observed that the presence of p53AD at the promoter had a major impact on Pol II promoter clearance and Pol II CTD phosphorylation both in vitro and in cells. Coupled with our electron microscopy analysis of p53-Mediator, these results suggest that p53AD-Mediator structural shifts enable stalled Pol II complexes to transition off the promoter to a productively elongating state. Notably, p53AD-dependent formation of the pocket domain in Mediator does not appear necessary for Pol II recruitment; rather, formation of the pocket domain correlates with changes in Pol II processing and promoter escape. How might this occur? What surfaces in Mediator and Pol II are involved in this transition, and how might the Mediator-Pol II interface change during the p53AD-directed structural shift? Delineation of such questions will require further studies involving cryo-electron microscopy (cryo-EM) analysis of structurally distinct p53-Mediator-Pol II assemblies.
We observed substantial differences in TFIIH-dependent Pol II CTD phosphorylation in PECs assembled in the presence of WT p53 compared to that of PECs assembled without an activator or with the oncogenic p53QS mutant. Given the Mediator requirement for Pol II CTD phosphorylation in the PEC, these observations, considered together with the functional and structural data, define a mechanism by which p53 precisely coordinates Mediator structural shifts, Pol II activation and TFIIH-dependent Pol II CTD phosphorylation. Yeast Mediator is known to physically interact with TFIIH 3 , hinting that Mediator structural shifts might directly impact TFIIH structure and function in the PEC. Immobilized template assays at the native HDM2 promoter revealed a Mediator requirement for TFIIH-dependent Pol II CTD phosphorylation in the fully assembled PEC. This result indicates that, in this context, Mediator must properly orient the Pol II CTD for efficient phosphorylation by TFIIH. We performed immobilized template assays in the presence of WT p53 or the oncogenic p53QS mutant as well as in the absence of an activator. Notably, Pol II CTD phosphorylation occurred in each circumstance, although transcripts were generated only in the presence of WT p53. These results indicate that Pol II CTD phosphorylation per se does not correlate with activation of transcription; these data also introduce the intriguing possibility that, in these different contexts (Mediator structure will be different in each case), alterations in the Pol II CTD phosphorylation pattern might underlie the stark differences in Pol II activity.
In addition to Mediator, the p53AD has been shown to interact with other PEC components, including TFIID and TFIIH, and these interactions may play alternate roles in activation [36] [37] [38] . However, a p53AD affinity column purifies only the Mediator complex from the P1M/Q1M fraction, with no detectable co-purifying of TFIID or TFIIH (Supplementary Fig. 8a-c) . Because the P1M/Q1M fraction is enriched in TFIID and TFIIH as well as in Mediator, this suggests that potential p53AD interactions with TFIID or TFIIH are of much lower affinity. It is also notable that there is a Mediator requirement for activated transcription (that is, not basal transcription) in both yeast and human systems, highlighting Mediator's essential role in activator-dependent transcription 39, 40 . Yet we cannot exclude the possibility that secondary p53AD interactions with TFIID or TFIIH might have auxiliary roles in activating transcription. Moreover, posttranslational modifications in p53AD may regulate these interactions in specific promoter contexts 41, 42 . Other co-regulatory factors, including CBP/p300 and HDM2, are targeted by p53AD and clearly have important roles in regulating p53-dependent gene expression 16, 43, 44 . It is currently unclear how the binding of these and other factors might be coordinately regulated; however, because four activation domains could potentially mediate p53-cofactor interactions at the promoter, multiple factors might interact with p53 simultaneously.
Finally, many p53-regulated genes feature Pol II and other factors preloaded at the promoter 21 . Because even transient reactivation of p53 can cause tumor regression 45, 46 , a strategy to reactivate certain p53 target genes might involve agents that trigger p53AD-specific structural shifts in Mediator, perhaps by targeting the p53AD-Med17 interface.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/nsmb/.
Note: Supplementary information is available on the Nature Structural & Molecular Biology website. Figure 7 The pocket domain represents a common structural feature in activator-bound Mediator. Shown are 'bottom' views of Mediator complexes bound to different activation domains. The location of the pocket is noted by the arrows. Mediator structures labeled 'active' have been shown to activate transcription in a reconstituted system. Note that transcriptionally inactive structures (unliganded Mediator or p53CTD-Mediator structure) lack the pocket domain. The unliganded Mediator structure is not bound to an activator 18 . Studies with both yeast 4 and human Mediator ( Supplementary Fig. 12c ) reveal that the pocket domain represents the Pol II binding site in Mediator. For reference, the structure of the yeast Pol II enzyme 49 (PDB 1Y1V) is also shown to the same relative scale.
